Chronic Heart Failure - Pipeline Review, H2 2015

Published: Nov, 2015 | Pages: 167 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chronic Heart Failure - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Chronic Heart Failure - Pipeline Review, H2 2015', provides an overview of the Chronic Heart Failure's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Heart Failure
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chronic Heart Failure and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chronic Heart Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Heart Failure pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Heart Failure
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Heart Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Chronic Heart Failure Overview 10
Therapeutics Development 11
Pipeline Products for Chronic Heart Failure - Overview 11
Pipeline Products for Chronic Heart Failure - Comparative Analysis 12
Chronic Heart Failure - Therapeutics under Development by Companies 13
Chronic Heart Failure - Therapeutics under Investigation by Universities/Institutes 15
Chronic Heart Failure - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Chronic Heart Failure - Products under Development by Companies 19
Chronic Heart Failure - Products under Investigation by Universities/Institutes 20
Chronic Heart Failure - Companies Involved in Therapeutics Development 21
Amgen Inc. 21
AnGes MG, Inc. 22
ARCA biopharma, Inc. 23
Bayer AG 24
Bial - Portela & Ca, S.A. 25
Caladrius Biosciences, Inc. 26
Capricor Therapeutics, Inc. 27
Celyad SA 28
Jiangsu Hengrui Medicine Co., Ltd. 29
Juventas Therapeutics, Inc. 30
Laboratoires Pierre Fabre SA 31
Les Laboratoires Servier SAS 32
Mast Therapeutics, Inc. 33
Mesoblast Limited 34
Novartis AG 35
Pfizer Inc. 36
PhaseBio Pharmaceuticals, Inc. 37
Sanofi 38
Stemedica Cell Technologies, Inc. 39
Vichem Chemie Research Ltd. 40
Zensun (Shanghai) Sci & Tech Co., Ltd. 41
Chronic Heart Failure - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Target 44
Assessment by Mechanism of Action 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
(sacubitril + valsartan) - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
aliskiren fumarate - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
BAY-1067197 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
beperminogene perplasmid - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
BIA-51058 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
C3BSCQR-1 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
carvedilol phosphate ER - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
cenderitide - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
CLBS-14 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
F-373280 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
finerenone - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
furosemide - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
ivabradine hydrochloride - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
JVS-100 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Mesenchymal Stem Cells - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MPC-150IM - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Neucardin - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
omecamtiv mecarbil MR - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
PB-1046 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
rivaroxaban - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
RNAi Gene Therapy to Inhibit STIM1 for Chronic Heart Failure and Atherosclerosis - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
SAR-296968 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
serelaxin - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
sildenafil citrate - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Small Molecules for Chronic Heart Failure - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
vepoloxamer - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
vericiguat - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Chronic Heart Failure - Recent Pipeline Updates 106
Chronic Heart Failure - Dormant Projects 153
Chronic Heart Failure - Discontinued Products 154
Chronic Heart Failure - Product Development Milestones 155
Featured News & Press Releases 155
Nov 10, 2015: Novartis heart failure medicine Entresto substantially cuts 30-day hospital readmissions, new post-hoc analysis shows 155
Nov 09, 2015: Vepoloxamer Nonclinical Study Results In Advanced Heart Failure To Be Presented At 2015 American Heart Association Scientific Sessions 156
Nov 08, 2015: Amgen And Cytokinetics Announce Late-Breaking Presentation Of COSMIC-HF Trial At AHA Scientific Sessions 2015 156
Nov 06, 2015: Latest Clinical Data of Vericiguat To Be Presented at Late-Breaking-Clinical-Trial Session at AHA 159
Nov 04, 2015: scPharmaceuticals Announces Positive Results from Pivotal Trial of its Novel Subcutaneous Furosemide Formulation in Patients with Heart Failure 159
Nov 02, 2015: Amgen To present abstracts on Corlanor At American Heart Association Scientific Sessions 2015 160
Oct 27, 2015: Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure 161
Oct 26, 2015: Mast Therapeutics Initiates Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure 163
Sep 29, 2015: Phase 2 Trial Results Show Mesoblast Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure 164
Sep 28, 2015: Mast Announces Presentation of Results of Nonclinical Study of Vepoloxamer in Chronic Heart Failure at the HFSA's Annual Scientific Meeting 165
Appendix 166
Methodology 166
Coverage 166
Secondary Research 166
Primary Research 166
Expert Panel Validation 166
Contact Us 166
Disclaimer 167

List of Tables

Number of Products under Development for Chronic Heart Failure, H2 2015 11
Number of Products under Development for Chronic Heart Failure - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Development, H2 2015 18
Products under Development by Companies, H2 2015 19
Products under Investigation by Universities/Institutes, H2 2015 20
Chronic Heart Failure - Pipeline by Amgen Inc., H2 2015 21
Chronic Heart Failure - Pipeline by AnGes MG, Inc., H2 2015 22
Chronic Heart Failure - Pipeline by ARCA biopharma, Inc., H2 2015 23
Chronic Heart Failure - Pipeline by Bayer AG, H2 2015 24
Chronic Heart Failure - Pipeline by Bial - Portela & Ca, S.A., H2 2015 25
Chronic Heart Failure - Pipeline by Caladrius Biosciences, Inc. , H2 2015 26
Chronic Heart Failure - Pipeline by Capricor Therapeutics, Inc., H2 2015 27
Chronic Heart Failure - Pipeline by Celyad SA, H2 2015 28
Chronic Heart Failure - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015 29
Chronic Heart Failure - Pipeline by Juventas Therapeutics, Inc., H2 2015 30
Chronic Heart Failure - Pipeline by Laboratoires Pierre Fabre SA, H2 2015 31
Chronic Heart Failure - Pipeline by Les Laboratoires Servier SAS, H2 2015 32
Chronic Heart Failure - Pipeline by Mast Therapeutics, Inc., H2 2015 33
Chronic Heart Failure - Pipeline by Mesoblast Limited, H2 2015 34
Chronic Heart Failure - Pipeline by Novartis AG, H2 2015 35
Chronic Heart Failure - Pipeline by Pfizer Inc., H2 2015 36
Chronic Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2015 37
Chronic Heart Failure - Pipeline by Sanofi, H2 2015 38
Chronic Heart Failure - Pipeline by Stemedica Cell Technologies, Inc., H2 2015 39
Chronic Heart Failure - Pipeline by Vichem Chemie Research Ltd., H2 2015 40
Chronic Heart Failure - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2015 41
Assessment by Monotherapy Products, H2 2015 42
Assessment by Combination Products, H2 2015 43
Number of Products by Stage and Target, H2 2015 45
Number of Products by Stage and Mechanism of Action, H2 2015 47
Number of Products by Stage and Route of Administration, H2 2015 49
Number of Products by Stage and Molecule Type, H2 2015 51
Chronic Heart Failure Therapeutics - Recent Pipeline Updates, H2 2015 106
Chronic Heart Failure - Dormant Projects, H2 2015 153
Chronic Heart Failure - Discontinued Products, H2 2015 154